Peptide-Based Cardiac Imaging: Beyond Heart Scans

Peptide Cardiac Imaging

87%

of post-MI patients showed patchy RGD peptide uptake at or around ischemic regions, revealing active cardiac repair invisible to standard perfusion imaging.

Chen et al., Theranostics, 2016

Chen et al., Theranostics, 2016

View as image

Traditional cardiac imaging tells you where blood flows and where it does not. Perfusion scans with technetium-99m sestamibi or rubidium-82 PET reveal areas of reduced blood supply, but they cannot distinguish between a heart that is actively repairing itself and one that has stopped trying. They cannot identify amyloid protein infiltrating the myocardium. They cannot track whether an angiogenic therapy is actually growing new blood vessels. Peptide-based radiotracers address these gaps by targeting specific molecular processes in cardiac tissue: integrins expressed during angiogenesis, amyloid fibrils deposited in cardiomyopathy, apoptosis markers on dying cells, and inflammatory mediators recruited after injury. For the foundational technique of imaging dying heart cells, see Annexin V: The Apoptosis Peptide That Images Dying Heart Cells.

How Peptide Tracers Differ from Perfusion Imaging

Standard myocardial perfusion imaging (MPI) uses radiotracers that distribute based on blood flow. Regions with adequate perfusion light up; ischemic or infarcted regions appear as defects. This tells you the consequence of coronary artery disease but nothing about the molecular biology occurring within the tissue.

Peptide-based radiotracers bind to specific molecular targets. Instead of passively distributing with blood flow, they actively seek out receptors, proteins, or structural elements that indicate a particular disease process. An RGD peptide labeled with gallium-68 binds to αvβ3 integrin, which is upregulated on proliferating endothelial cells during angiogenesis. A somatostatin analog labeled with fluorine-18 binds to somatostatin receptors on inflammatory cells. An amyloid-binding peptide labeled with iodine-124 binds to amyloid fibrils deposited in the myocardium.

This molecular specificity means peptide tracers can answer questions that perfusion imaging cannot: Is the heart growing new blood vessels after a heart attack? Is there active inflammation in the myocardium? Has amyloid protein infiltrated the heart muscle?

RGD Peptides: Imaging Angiogenesis After Heart Attack

After myocardial infarction, the heart mounts a repair response that includes angiogenesis (new blood vessel formation) in and around the infarcted zone. Integrin αvβ3, a transmembrane receptor, is upregulated on the surface of proliferating endothelial cells and can be imaged with radiolabeled RGD (arginine-glycine-aspartate) peptides.

Tateishi et al. (2012) reviewed radiolabeled RGD peptides as integrin-targeted PET tracers, documenting the development of multiple RGD-based radiotracers including 18F-galacto-RGD, 68Ga-NOTA-RGD, and multimeric variants designed for higher binding affinity.^[1]

Chen et al. (2016) brought the clinical evidence, showing that [68Ga]NOTA-PRGD2 PET/CT detected integrin αvβ3-related repair in 87% (20/23) of post-MI patients, with patchy radiotracer uptake at or immediately around the ischemic regions.^[2] This uptake was invisible on conventional perfusion imaging. The signal reflected active angiogenesis and tissue repair, not just blood flow deficits.

Eo et al. (2016) demonstrated the therapeutic implications of angiogenesis imaging with 68Ga-RGD PET, showing that the degree of RGD uptake after MI correlated with regional and global left ventricular dysfunction.^[3] Increased integrin expression in the infarct zone predicted subsequent remodeling, making RGD PET a potential prognostic tool. Patients with robust angiogenic responses might have better outcomes; those without might benefit from pro-angiogenic therapies.

For a deeper look at integrin imaging specifically in the post-MI setting, see Integrin Imaging After Heart Attack: Tracking Cardiac Repair.

Evuzamitide: Peptide Imaging for Cardiac Amyloidosis

Cardiac amyloidosis occurs when misfolded proteins deposit as amyloid fibrils in the myocardium, causing progressive stiffening and heart failure. Diagnosis has historically relied on echocardiography, cardiac MRI, and technetium pyrophosphate scintigraphy, but these methods have limitations in specificity and early detection.

Evuzamitide ([124I]I-AT-01, also called p5+14) is a synthetic peptide that binds directly to amyloid fibrils. Labeled with iodine-124 for PET imaging, it provides molecular-specific detection of amyloid deposits in the heart and other organs. In August 2024, the FDA granted evuzamitide Breakthrough Therapy designation for clinical assessment of patients with known or suspected cardiac amyloidosis.

The peptide p5+14 binds to a common structural motif present in amyloid fibrils regardless of the precursor protein (whether transthyretin, light chain, or other), making it a pan-amyloid imaging agent. This contrasts with technetium pyrophosphate, which is more selective for transthyretin amyloidosis and less reliable for AL (light chain) amyloidosis.

Di Nora et al. (2025) explored the associations between technetium pyrophosphate scintigraphy, echocardiography, and cardiac biomarkers in cardiac amyloidosis, highlighting the need for molecular-specific imaging tools that can detect amyloid directly rather than inferring its presence from structural changes.^[4]

NT-proBNP: The Peptide Biomarker That Monitors the Heart

While not an imaging tracer, NT-proBNP (N-terminal pro-B-type natriuretic peptide) is the most widely used peptide-based tool in cardiac diagnostics. When cardiomyocytes are stretched by volume or pressure overload, they release proBNP, which is cleaved into the active hormone BNP and the inactive fragment NT-proBNP. Blood levels of NT-proBNP serve as a biomarker for heart failure severity, treatment response, and prognosis.

Richards et al. (2004) established NT-proBNP's role in heart failure therapy decisions and monitoring, showing that serial NT-proBNP measurements could guide treatment intensification and track response to therapy.^[5] Semenov et al. (2018) addressed the standardization challenges of BNP and NT-proBNP immunoassays, noting that the diverse molecular forms of circulating natriuretic peptides complicate accurate measurement across different assay platforms.^[6]

Petrie et al. (2024) published findings from the STEP-HFpEF program showing that semaglutide reduced NT-proBNP levels in obese patients with heart failure with preserved ejection fraction, demonstrating how a peptide biomarker can track the cardiac benefits of a peptide drug.^[7]

For the full story of natriuretic peptide diagnostics, see BNP and NT-proBNP: How Heart Failure Is Diagnosed with Peptide Biomarkers and Natriuretic Peptide-Guided Therapy: Using a Biomarker to Adjust Treatment.

Somatostatin Receptor Imaging: From Oncology to Cardiology

Somatostatin receptor (SSTR) imaging with radiolabeled peptides like 68Ga-DOTATATE and 68Ga-DOTATOC is standard practice for neuroendocrine tumor staging. These peptides bind to SSTR2 expressed on tumor cells, enabling precise localization with PET.

The same receptors are expressed on activated macrophages involved in cardiac inflammation. Researchers are adapting SSTR imaging to detect myocardial inflammation in conditions like cardiac sarcoidosis, myocarditis, and post-MI inflammatory remodeling. Dubash et al. (2024) compared [18F]FET-BAG-TOCA (a fluorine-18 labeled somatostatin analog) with standard 68Ga-DOTA-peptide PET in patients, demonstrating the feasibility of somatostatin receptor-targeted cardiac inflammation imaging.^[8]

The advantage of somatostatin peptide tracers over FDG (the standard PET tracer for inflammation) is specificity. FDG uptake reflects glucose metabolism in any metabolically active cell, including normal cardiomyocytes, requiring complex dietary preparation to suppress myocardial background signal. Somatostatin peptides bind specifically to inflammatory cells, providing cleaner images without dietary manipulation.

For the oncology applications of these tracers, see OctreoScan: The Original Somatostatin Receptor Imaging Agent and Lutathera (177Lu-DOTATATE): How Radioactive Peptides Treat Cancer.

Emerging Peptide Cardiac Tracers

Thymosin Beta-4 and Cardiac Fibrosis

Wang et al. (2022) demonstrated that thymosin beta-4 protects against cardiac damage and subsequent fibrosis in mice with myocardial infarction.^[9] While thymosin beta-4 is being studied as a therapeutic peptide rather than an imaging agent, the fibrotic processes it modulates are themselves targets for peptide-based imaging. Radiolabeled peptides that bind to fibrosis markers (collagen, matrix metalloproteinases, fibroblast activation protein) are in development for detecting and quantifying cardiac fibrosis, which is currently assessed only by cardiac MRI with gadolinium.

Troponin and High-Sensitivity Cardiac Biomarkers

High-sensitivity cardiac troponin assays represent another peptide-based diagnostic tool. Andrews et al. (2025) evaluated the utility of combining high-sensitivity cardiac troponin-T with NT-proBNP for predicting incident heart failure, finding that the dual-biomarker approach improved risk stratification beyond either marker alone.^[10] De Michieli et al. (2025) showed that high-sensitivity cardiac troponin I provided risk stratification in wild-type transthyretin amyloid cardiomyopathy, connecting peptide biomarkers back to the amyloid imaging story.^[11]

Next-Generation Radionuclides

Xue et al. (2026) developed an FGF2-based cyclic peptide PET tracer for noninvasive detection of receptor expression, demonstrating the ongoing innovation in peptide tracer design that could be adapted for cardiac applications targeting fibroblast growth factor receptors involved in cardiac remodeling.^[12] The trend is toward fluorine-18 labeled peptides (half-life 110 minutes), which allow centralized production and distribution, unlike gallium-68 tracers that require an on-site generator. For more on this technical evolution, see 18F-Labeled Peptide PET Tracers: Longer Half-Life, Different Applications.

The Molecular Imaging Shift

The trajectory of peptide-based cardiac imaging follows a clear pattern: from detecting consequences (perfusion deficits, structural changes) to identifying causes (amyloid deposition, integrin-driven angiogenesis, somatostatin receptor-positive inflammation). Each peptide tracer provides a different molecular readout, and combinations of tracers could produce a comprehensive molecular profile of cardiac disease.

For a patient who presents with heart failure, the future molecular imaging workup might include: NT-proBNP for severity assessment, evuzamitide PET to rule out amyloidosis, RGD PET to assess angiogenic capacity, and SSTR PET to quantify inflammation. Each of these uses peptide-target interactions that traditional imaging cannot replicate.

The Bottom Line

Peptide-based cardiac imaging is expanding from perfusion assessment to molecular disease characterization. RGD peptide PET detects post-MI angiogenesis in 87% of patients, providing prognostic information invisible to standard scans. Evuzamitide, a peptide PET tracer for cardiac amyloidosis, received FDA Breakthrough Therapy designation in 2024. Somatostatin receptor peptide imaging, proven in oncology, is being adapted for cardiac inflammation. NT-proBNP remains the foundational peptide biomarker for heart failure management. Together, these peptide-based tools are transforming cardiac diagnostics from anatomy-based to molecule-based assessment.

Frequently Asked Questions

What is peptide-based cardiac imaging?

Peptide-based cardiac imaging uses synthetic peptides labeled with radioactive isotopes (gallium-68, fluorine-18, iodine-124) as targeted PET or SPECT tracers. Unlike standard perfusion imaging that shows blood flow patterns, these peptides bind to specific molecular targets in the heart: integrins on new blood vessels, amyloid fibrils in cardiomyopathy, or somatostatin receptors on inflammatory cells. This provides information about the molecular processes driving cardiac disease, not just their structural consequences.

How do RGD peptides image heart repair after a heart attack?

After myocardial infarction, the heart grows new blood vessels (angiogenesis) to restore blood supply. Proliferating endothelial cells express integrin αvβ3 on their surface. RGD (arginine-glycine-aspartate) peptides bind specifically to this integrin. When labeled with gallium-68 or fluorine-18 for PET scanning, RGD peptides reveal where active angiogenesis is occurring. In clinical studies, 87% of post-MI patients showed RGD uptake at or around infarct zones, invisible on standard perfusion scans.

What is evuzamitide for cardiac amyloidosis?

Evuzamitide ([124I]I-AT-01) is a synthetic peptide labeled with iodine-124 that binds directly to amyloid fibrils deposited in the heart. It received FDA Breakthrough Therapy designation in August 2024 for cardiac amyloidosis imaging. Unlike technetium pyrophosphate scintigraphy, which works best for transthyretin amyloidosis, evuzamitide binds to a common structural motif present in all amyloid types, making it a pan-amyloid imaging agent that can detect both ATTR and AL cardiac amyloidosis.

What is NT-proBNP and how is it used in heart failure?

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a peptide fragment released by heart muscle cells when they are stretched by volume or pressure overload. Blood levels correlate with heart failure severity and prognosis. Cardiologists use serial NT-proBNP measurements to diagnose heart failure, guide treatment intensity, and monitor response to therapy. Recent data from the STEP-HFpEF program showed that semaglutide reduced NT-proBNP in obese heart failure patients.

Can somatostatin receptor imaging detect heart inflammation?

Yes, in early clinical studies. Somatostatin receptors (particularly SSTR2) are expressed on activated macrophages involved in cardiac inflammation. Radiolabeled somatostatin peptides like 68Ga-DOTATATE, already standard for neuroendocrine tumor imaging, can detect macrophage-driven inflammation in cardiac sarcoidosis and myocarditis. The advantage over FDG-PET is specificity: somatostatin peptides target inflammatory cells directly without the confounding myocardial glucose uptake that complicates FDG cardiac imaging.

What peptide cardiac imaging tracers are in development?

Beyond RGD integrin tracers and evuzamitide for amyloidosis, researchers are developing peptides targeting cardiac fibrosis markers (collagen, fibroblast activation protein), inflammatory receptors (somatostatin, chemokine receptors), and growth factor receptors involved in cardiac remodeling. The trend is toward fluorine-18 labeled peptides, which have a 110-minute half-life allowing centralized production and distribution, compared to gallium-68 tracers that require on-site generators.